Meyka Pro banner
AnaptysBio, Inc.

AnaptysBio, Inc. (ANAB) Stock Overview

Explore AnaptysBio, Inc.’s financial performance, market position, analyst ratings, and future outlook.

ANAB●NASDAQ
HealthcareBiotechnology
$46.63
$0.77(1.62%)
U.S. Market opens in 34h 12m

AnaptysBio, Inc. (ANAB)

Meyka AI Score

Z

Key Financials

Market Cap1.4B
P/E Ratio7.31
EPS (TTM)$-1.08
ROE9.07%
Fundamental Analysis

AI Price Forecasts

1 Month$56.43
3 Months$74.68
1 Year Target$62.18

ANAB Stock Analysis & Investment Overview (NASDAQ)

Our AI-powered analysis of AnaptysBio, Inc. (NASDAQ: ANAB) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of B+, AnaptysBio, Inc.'s NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.

The current technical analysis of ANAB on the NASDAQ shows an RSI of 44.77, suggesting the stock is in a a neutral condition. Our forecasting models predict a 12-month price target of $62.18 for the NASDAQ listing.

Key metrics behind AnaptysBio, Inc.'s NASDAQ-traded stock include a P/E ratio of 7.31 and a market capitalization of 1.4B. Combined with our AI analysis, these give both institutional and retail investors a clear view of ANAB on the NASDAQ.

Price Performance (NASDAQ: ANAB)

1-Day Change
-1.62%
5-Day Change
3.004%
1-Month Change
2.64%
3-Month Change
-17.75%
6-Month Change
-22.39%
Year-to-Date (YTD) Change
44.28%
1-Year Change
85.70%
3-Year Change
382.21%
5-Year Change
127.57%
All-Time (Max) Change
311.56%

Contact Information

858 362 6295
10770 Wateridge Circle, San Diego, CA, 92121

Company Facts

1,040 Employees
IPO DateJan 26, 2017
CountryUS
Actively Trading

Frequently Asked Questions